Ghosh Manashi, Muneer A, Trivedi Vinita, Mandal Kaustav, Shubham Santosh
Junior Consultant, Department of Radiation Oncology, Mahavir Cancer Sansthan, Patna, Bihar, India.
Postgraduate Resident, Department of Radiation Oncology, Mahavir Cancer Sansthan, Patna, Bihar, India.
J Clin Diagn Res. 2017 Aug;11(8):XR01-XR03. doi: 10.7860/JCDR/2017/27977.10472. Epub 2017 Aug 1.
Metaplastic Breast Carcinoma (MBC) is a rare heterogeneous group of primary breast malignancies with different subgroups; exhibits a variety of histopathologic patterns and appears to be both epithelial and mesenchymal in origin. The ideal treatment for MBC remains unknown, due to its low incidence and pathological variability. Owing to its rarity, MBC has been treated as a variant of Invasive Duct Carcinoma (IDC). But it has poorer prognosis as compared to IDC. This is a case series to evaluate clinicopathologic characteristics and the multi-disciplinary treatment of nine MBC patients treated in a single institute.
化生性乳腺癌(MBC)是一组罕见的原发性乳腺恶性肿瘤,具有不同亚组,表现出多种组织病理学模式,其起源似乎兼具上皮和间充质成分。由于其发病率低和病理变异性,MBC的理想治疗方法仍不明确。由于其罕见性,MBC一直被视为浸润性导管癌(IDC)的一种变体。但与IDC相比,其预后较差。这是一个病例系列,旨在评估在单一机构接受治疗的9例MBC患者的临床病理特征和多学科治疗情况。